EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)

Hatice Bolek, Satı Coskun Yazgan, Furkan Ceylan, Jorge Esteban-Villarrubia, Cagatay Arslan, Tülay Kuş, Deniz Tural, Mehmet Ali Nahit Sendur, Nuriye Ozlem Kucuk, Elif Çıngı Özdemir, Elena Castro, Emre Yekedüz und 1 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115226 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Hatice Bolek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara University Cancer Institute, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Taxoids, Heterocyclic Compounds, 1-Ring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumTaxoidsHeterocyclic Compounds, 1-RingDipeptidesRadiopharmaceuticalsHumansMaleRetrospective StudiesAgedMiddle AgedAged, 80 and overRadioisotopesNeoplasm MetastasisProgression-Free SurvivalProstate-Specific Antigen

Stichwörter der Autor:innen

CabazitaxelLutetiumProstate cancerPsma

Substanzen

cabazitaxelLutetiumTaxoidsHeterocyclic Compounds, 1-RingDipeptidesLutetium-177RadioisotopesRadiopharmaceuticalsPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey; Ankara University Cancer Institute, Ankara, Turkey.
  • Bilkent City Hospital, Department of Medical Oncology, Ankara, Turkey.
  • 12 de Octubre University Hospital, Department of Medical Oncology, Madrid, Spain.
  • Izmir University of Economics, Medical Point Hospital, Izmir, Turkey.
  • Gaziantep University School of Medicine, Department of Medical Oncology, Gaziantep, Turkey.
  • Koc University Medical Faculty, Department of Medical Oncology, Istanbul, Turkey.

Förderung

  • Gilead Sciences

Zitieren

APA

Bolek, H., Yazgan, S. C., Ceylan, F., Esteban-Villarrubia, J., Arslan, C., Kuş, T., Tural, D., Sendur, M. A. N., Kucuk, N. O., Çıngı Özdemir, E., Castro, E., Yekedüz, E., & Ürün, Y. (2025). Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115226

Vancouver

Bolek H, Yazgan SC, Ceylan F, Esteban-Villarrubia J, Arslan C, Kuş T, et al. Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115226

BibTeX
@article{Bolek2025,
  author = {Bolek, Hatice and Yazgan, Satı Coskun and Ceylan, Furkan and Esteban-Villarrubia, Jorge and Arslan, Cagatay and Kuş, Tülay and Tural, Deniz and Sendur, Mehmet Ali Nahit and Kucuk, Nuriye Ozlem and Çıngı Özdemir, Elif and Castro, Elena and Yekedüz, Emre and Ürün, Yüksel},
  title = {Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115226}
}
Kostenlos starten →